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Abstract: Design and synthesis of an new scaffold as HDAC inhibitor and its merger with three tubulin binders to create releasable conjugate compounds is described. The biological evaluation includes: a) in vitro reactivity with glutathione, b) antiproliferative activity, c) cell cycle analysis and d) quantification of protein acetylation. The cellular pharmacology study indicated that the HDAC-inhibitor-drug conjugates retained antimitotic and proapoptotic activity with a reduced potency.



























In our first plan, we studied the use of LBH589 (6) that we prepared according the reported procedure but we had several problems in the formation of the dimeric structure due to the presence of the indole nitrogen. As consequence we designed the structure where the indole nucleus is removed and replaced by a phenyl group. We picked out compound 19 as our first goal. This was prepared in a 5-step sequence using benzylamine and methyl ester 8 of 4-formylcinnamic acid (7) as building blocks. The crucial reductive amination step furnished compound 9 permitting the formation of the required hydroxamic acid by subsequent manipulation of the ester function.​[15]​ In particular this was realized by base-catalyzed ester hydrolysis and condensation reaction with protected hydroxylamine (NH2OTHP) in the presence of EDC and HOBt to give compound 16 that was finally deprotected by camphorsulfonic acid (CSA) to give 19. 
In a general  attempt to obtain the desired hybrids we planned to use the benzylic NH nitrogen for the introduction of  the dithiodiacyl spacers to take in the second scaffold (tubulin binder unities). Surprisingly and without any plausible explanation, acylation of 19 and 16 with 4,4’-dithiobutyric acid proved tricky and the corresponding amide could not be isolated.  For this reason we realised the opportunity to move the  acylation point out from the encumbered nitrogen and far from the disulfide moiety.  Compounds 18 and 20 were therefore synthesized according to Scheme 2. N-hydroxymethylester 10 was prepared by reaction of ester 14, obtained by reduction of 7 with NaBH4 in the presence of Dowex1-x8,​[16]​ with 2-benzylamino ethanol in the presence of DIPEA. Manipulation of the carboxylic function required: a) ester hydrolysis and successively b) protection of the hydroxyl group as acetate to give compound 13. Reaction of 13 with NH2OTHP in the presence of EDC and HOBt furnished compound 17, that was converted into compound 18 by potassium carbonate hydrolysis of the acetate ester. The need to have at hand compound 20 as reference compound for biological evaluation drove us to submit compound 18 to reaction with CSA in MeOH. In this case the critical purification step was carried out by filtration on SPE ISOLUTE PE-AX (quaternary amine functionalized silica).  We used compound 11 as starting material for the preparation of reference compounds 16a and 19a (see experimental section).





















- In vitro reactivity with L-Glutathione
We first investigated  from a chemical point of view if glutathione is really able to cleave the disulfide bond of the conjugate compounds 24, 28 and 30. Solution of these (1.8 mM, acetone/water 1:1) were treated with L-glutathione (1.8 mM) for 6 h and the mixtures was directly analysed by HRESI-FT-MS. The experiment is far from the idea to reproduce the cellular medium but the detected ionic species offer a qualitative evidence of the release of the drugs. (Table 1 ).























The antiproliferative activity of the tested antimicrotubule agents (thiocolchicine 1, paclitaxel 3 and  cephalomannine 4), HDAC inhibitor moieties 19 and 20, N-Boc derivatives 16a and 19a and conjugate compounds was evaluated under the same conditions following 72 h-exposure in ovarian carcinoma cells (IGROV-1) (Table 2). All tested compounds exhibited a significant antiproliferative activity in a submicromolar range apart from N-Boc derivative 16a and 19a. However, all conjugated compounds were characterized by a substantial reduction of activity, as compared with free antimicrotubule agent most evident in the paclitaxel conjugate (28). Among the tested conjugates, the thiocolchicine analogue (24) was the most effective and therefore used for additional cellular and biochemical pharmacological studies. Again, the compound 24 exhibited a reduction of potency as compared to thiocolchicine.1 Since  a comparable reduction of potency was found with the thiocolchicine dimer containing the same mercapto-acylated linker, it is conceivable that the presence of this side chain may affect the activity of the released thiocolchicine derivative. 
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